

1. Sales January to March 2008 and 2007

	2008	2007	% change	
	CHF m	CHF m	In CHF	In local currencies
January – March				
Pharmaceuticals Division	8,568	9,142	-6	+1
Roche Pharmaceuticals	5,498	5,702	-4	+1
Genentech	2,399	2,547	-6	+9
Chugai	671	893	-25	-23
Diagnostics Division	2,287	2,216	+3	+9
Roche Group	10,855	11,358	-4	+2

2. Sales January to March 2008 and 2007 excluding Pandemic Tamiflu*

	2008	2007	% change	
	CHF m	CHF m	In CHF	In local currencies
January – March				
Pharmaceuticals Division	8,523	8,396	+2	+9
Roche Pharmaceuticals	5,455	5,151	+6	+11
Genentech	2,399	2,547	-6	+9
Chugai	669	698	-4	-2
Diagnostics Division	2,287	2,216	+3	+9
Roche Group	10,810	10,612	+2	+9

* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

3. Quarterly local sales growth by Division in 2007 and 2008

	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007
Pharmaceuticals Division	+16	+6	+5	+1
Roche Pharmaceuticals	+13	+1	+7	+1
Genentech	+26	+18	+6	+9
Chugai	+2	+8	-8	-23
Diagnostics Division	+5	+4	+8	+9
Roche Group	+13	+6	+6	+2

4. Quarterly local sales growth by Division in 2007 and 2008 excluding Pandemic Tamiflu*

	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007
Pharmaceuticals Division	+14	+12	+11	+9
Roche Pharmaceuticals	+11	+10	+14	+11
Genentech	+26	+18	+6	+9
Chugai	+4	+4	+4	-2
Diagnostics Division	+5	+4	+8	+9
Roche Group	+12	+10	+10	+9

* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

5. Quarterly sales by Division in 2007 and 2008

CHF millions	Q1 2007	Q2 2007	Q3 2007	Q4 2007	Q1 2008
Pharmaceuticals Division	9,142	9,126	8,856	9,659	8,568
Roche Pharmaceuticals	5,702	5,665	5,425	6,178	5,498
Genentech	2,547	2,680	2,623	2,564	2,399
Chugai	893	781	808	917	671
Diagnostics Division	2,216	2,343	2,264	2,527	2,287
Roche Group	11,358	11,469	11,120	12,186	10,855

6. Quarterly sales by Division in 2007 and 2008 excluding Pandemic Tamiflu*

CHF millions	Q1 2007	Q2 2007	Q3 2007	Q4 2007	Q1 2008
Pharmaceuticals Division	8,396	8,666	8,664	9,201	8,523
Roche Pharmaceuticals	5,151	5,203	5,314	5,736	5,455
Genentech	2,547	2,680	2,623	2,564	2,399
Chugai	698	783	727	901	669
Diagnostics Division	2,216	2,343	2,264	2,527	2,287
Roche Group	10,612	11,009	10,928	11,728	10,810

* excluding government & corporate pandemic Tamiflu sales; including seasonal Tamiflu sales

7. Top 20 Pharmaceuticals Division product sales¹ and local growth² in YTD March 2008: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	1,407	17%	675	14%	43	13%	689	21%
Herceptin	1,225	11%	363	9%	42	16%	820	12%
Avastin	1,131	35%	642	13%	28	-	461	78%
CellCept	487	11%	215	14%	8	13%	264	8%
NeoRecormon/Epogin	442	-13%	-	-	103	-16%	339	-13%
Pegasys	369	-3%	81	-10%	19	98%	269	-4%
Tarceva	286	28%	119	10%	8	-	159	40%
Xeloda	281	13%	89	16%	8	48%	184	11%
Tamiflu	278	-64%	234	83%	16	-93%	28	-94%
Bonviva/Boniva	241	56%	153	47%	-	-	88	77%
Lucentis	215	-5%	215	-5%	-	-	-	-
Xenical	136	-11%	14	-35%	-	-	122	-7%
Xolair	125	6%	125	6%	-	-	-	-
Valcyte/Cymevene	125	9%	54	11%	-	-	71	8%
Pulmozyme	117	15%	61	10%	-	-	56	22%
Nutropin	97	-5%	94	-6%	-	-	3	-1%
Neutrogen	95	1%	-	-	95	1%	-	-
Rocephin	91	-4%	3	-34%	13	9%	75	-3%
Activase/TNKase	83	-3%	71	-6%	-	-	12	30%
Madopar	74	0%	-	-	4	5%	70	0%

¹Roche Pharmaceuticals, Genentech and Chugai combined

² versus YTD March 2007

8. Top 20 Pharmaceuticals Division quarterly local product sales growth¹ in 2007 and 2008

	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007
MabThera/Rituxan	16%	17%	12%	17%
Herceptin	25%	18%	14%	11%
Avastin	39%	45%	41%	35%
CellCept	14%	4%	16%	11%
NeoRecormon/Epogin	-5%	-5%	-15%	-13%
Pegasys	7%	7%	14%	-3%
Tarceva	31%	28%	24%	28%
Xeloda	18%	20%	22%	13%
Tamiflu	25%	-60%	-46%	-64%
Bonviva/Boniva	123%	62%	63%	56%
Lucentis	1964%	31%	-9%	-5%
Xenical	-6%	-9%	-17%	-11%
Xolair	13%	11%	2%	6%
Valcyte/Cymevene	19%	9%	7%	9%
Pulmozyme	15%	14%	13%	15%
Nutropin	-2%	3%	-8%	-5%
Neutrogin	12%	15%	14%	1%
Rocephin	-2%	-2%	-4%	-4%
Activase/TNKase	20%	6%	-2%	-3%
Madopar	6%	5%	14%	0%

¹Roche Pharmaceuticals, Genentech and Chugai combined

9. Pharmaceuticals Division quarterly local product sales growth¹ US in 2007 and 2008

	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007
MabThera/Rituxan	12%	14%	4%	14%
Herceptin	3%	6%	1%	9%
Avastin	33%	37%	23%	13%
CellCept	18%	-1%	17%	14%
NeoRecormon/Epogin	-	-	-	-
Pegasys	-5%	-27%	-3%	-10%
Tarceva	-1%	1%	5%	10%
Xeloda	23%	30%	19%	16%
Tamiflu	196%	-71%	52%	83%
Bonviva/Boniva	77%	27%	40%	47%
Lucentis	1964%	31%	-9%	-5%
Xenical	-8%	-30%	-46%	-35%
Xolair	13%	11%	2%	6%
Valcyte/Cymevene	20%	4%	3%	11%
Pulmozyme	17%	14%	10%	10%
Nutropin	-2%	3%	-8%	-6%
Neutrogin	-	-	-	-
Rocephin	-7%	-13%	-32%	-34%
Activase/TNKase	24%	6%	0%	-6%
Madopar	-	-	-	-

¹Roche Pharmaceuticals and Genentech combined

10. Pharmaceuticals Division quarterly local product sales growth Japan¹ in 2007 and 2008

	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007
MabThera/Rituxan	6%	4%	2%	13%
Herceptin	25%	3%	0%	16%
Avastin	-	-	-	-
CellCept	14%	14%	18%	13%
NeoRecormon/Epogin	-3%	-12%	-22%	-16%
Pegasys	-5%	34%	53%	98%
Tarceva	-	-	-	-
Xeloda	6%	11%	14%	48%
Tamiflu	-93%	48%	-58%	-93%
Bonviva/Boniva	-	-	-	-
Lucentis	-	-	-	-
Xenical	-	-	-	-
Xolair	-	-	-	-
Valcyte/Cymevene	-	-	-	-
Pulmozyme	-	-	-	-
Nutropin	-	-	-	-
Neutrogen	12%	15%	14%	1%
Rocephin	5%	11%	-1%	9%
Activase/TNKase	-	-	-	-
Madopar	3%	2%	3%	5%

¹Chugai

11. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World¹ in 2007 and 2008

	Q2 2007 vs. Q2 2006	Q3 2007 vs. Q3 2006	Q4 2007 vs. Q4 2006	Q1 2008 vs. Q1 2007
MabThera/Rituxan	21%	23%	25%	21%
Herceptin	43%	26%	23%	12%
Avastin	52%	59%	80%	78%
CellCept	10%	9%	14%	8%
NeoRecormon/Epogin	-6%	-2%	-11%	-13%
Pegasys	13%	22%	20%	-4%
Tarceva	94%	68%	47%	40%
Xeloda	16%	15%	25%	11%
Tamiflu	-48%	-70%	-92%	-94%
Bonviva/Boniva	400%	278%	160%	77%
Lucentis	-	-	-	-
Xenical	-6%	-5%	-11%	-7%
Xolair	-	-	-	-
Valcyte/Cymevene	17%	15%	11%	8%
Pulmozyme	13%	14%	17%	22%
Nutropin	4%	-7%	-10%	-1%
Neutrogen	-	-	-	-
Rocephin	-2%	-4%	-3%	-3%
Activase/TNKase	-4%	1%	-16%	30%
Madopar	6%	5%	15%	0%

¹Roche Pharmaceuticals

12. Top Pharmaceuticals Division quarterly product sales¹ in 2007 and 2008

CHF millions	Q1 2007	Q2 2007	Q3 2007	Q4 2007	Q1 2008
MabThera/Rituxan	1,309	1,395	1,380	1,432	1,407
Herceptin	1,168	1,214	1,209	1,261	1,225
Avastin	923	986	1,062	1,135	1,131
CellCept	476	503	485	548	487
NeoRecormon/Epogin	522	544	518	510	442
Pegasys	400	407	383	447	369
Tarceva	243	260	271	288	286
Xeloda	267	282	290	312	281
Tamiflu	865	451	257	512	278
Bonviva/Boniva	170	204	230	283	241
Lucentis	263	261	239	228	215
Xenical	163	176	151	142	136
Xolair	136	148	145	138	125
Valcyte/Cymevene	124	137	137	144	125
Pulmozyme	111	120	124	128	117
Nutropin	117	122	118	113	97
Neutrogen	96	99	100	110	95
Rocephin	100	104	95	100	91
Activase/TNKase	96	106	92	88	83
Madopar	75	77	76	83	74

¹Roche Pharmaceuticals, Genentech and Chugai combined

13. Pharmaceuticals Division quarterly product sales¹ in US in 2007 and 2008

CHF millions	Q1 2007	Q2 2007	Q3 2007	Q4 2007	Q1 2008
MabThera/Rituxan	682	742	718	709	675
Herceptin	383	403	384	375	363
Avastin	657	689	718	693	642
CellCept	217	250	232	290	215
NeoRecormon/Epogin	-	-	-	-	-
Pegasys	104	107	75	111	81
Tarceva	125	125	121	129	119
Xeloda	89	109	114	123	89
Tamiflu	147	319	98	398	234
Bonviva/Boniva	120	135	150	190	153
Lucentis	263	261	239	228	215
Xenical	24	26	17	13	14
Xolair	136	148	145	138	125
Valcyte/Cymevene	56	70	69	73	54
Pulmozyme	65	67	68	67	61
Nutropin	114	118	115	108	94
Neutrogen	-	-	-	-	-
Rocephin	6	7	5	1	3
Activase/TNKase	88	94	80	76	71
Madopar	-	-	-	-	-

¹Roche Pharmaceuticals and Genentech combined

14. Pharmaceuticals Division quarterly product sales¹ in Japan in 2007 and 2008

CHF millions	Q1 2007	Q2 2007	Q3 2007	Q4 2007	Q1 2008
MabThera/Rituxan	38	48	49	55	43
Herceptin	36	45	39	44	42
Avastin	-	3	10	23	28
CellCept	7	9	9	10	8
NeoRecormon/Epogin	124	164	124	146	103
Pegasys	10	15	17	23	19
Tarceva	-	-	-	2	8
Xeloda	6	7	7	8	8
Tamiflu	246	-2	81	69	16
Bonviva/Boniva	-	-	-	-	-
Lucentis	-	-	-	-	-
Xenical	-	-	-	-	-
Xolair	-	-	-	-	-
Valcyte/Cymevene	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Nutropin	-	-	-	-	-
Neutrogen	96	99	100	110	95
Rocephin	12	16	14	16	13
Activase/TNKase	-	-	-	-	-
Madopar	4	5	4	6	4

¹Chugai

15. Pharmaceuticals Division quarterly product sales in Europe/Rest of World¹ in 2007 and 2008

CHF millions	Q1 2007	Q2 2007	Q3 2007	Q4 2007	Q1 2008
MabThera/Rituxan	589	605	613	668	689
Herceptin	749	766	786	842	820
Avastin	266	294	334	419	461
CellCept	252	244	244	248	264
NeoRecormon/Epogin	398	380	394	364	339
Pegasys	286	285	291	313	269
Tarceva	118	135	150	157	159
Xeloda	172	166	169	181	184
Tamiflu	472	134	78	45	28
Bonviva/Boniva	50	69	80	93	88
Lucentis	-	-	-	-	-
Xenical	139	150	134	129	122
Xolair	-	-	-	-	-
Valcyte/Cymevene	68	67	68	71	71
Pulmozyme	46	53	56	61	56
Nutropin	3	4	3	5	3
Neutrogen	-	-	-	-	-
Rocephin	82	81	76	83	75
Activase/TNKase	8	12	12	12	12
Madopar	71	72	72	77	70

¹ Roche Pharmaceuticals